

# Trajectory of migraine-related disability following long-term treatment with rizatriptan: results of the GLADIATOR study

Journal of Headache and Pain

21, 20

DOI: [10.1186/s10194-020-01088-4](https://doi.org/10.1186/s10194-020-01088-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The potential of lasmiditan in migraine. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096784.	3.5	17
2	Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study. Cephalalgia Reports, 2020, 3, 251581632095817.	0.7	8
3	Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. CNS Drugs, 2020, 34, 1015-1024.	5.9	7
4	Comprehensive management of adults with chronic migraine: Clinical practice guidelines in Mexico. Cephalalgia Reports, 2021, 4, 251581632110339.	0.7	0
5	Introduction of a smartphone based behavioral intervention for migraine in the emergency department. General Hospital Psychiatry, 2021, 69, 12-19.	2.4	8
6	Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review. Clinical Therapeutics, 2021, 43, 654-670.	2.5	1
7	Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain. Current Medical Research and Opinion, 2021, 37, 1031-1038.	1.9	5
8	Lasmiditan: an additional therapeutic option for the acute treatment of migraine. Expert Review of Neurotherapeutics, 2021, 21, 491-502.	2.8	6
9	Lasmiditan: Acute Migraine Treatment Without Vasoconstriction. A Review. Journal of Pharmacy Technology, 2021, 37, 244-253.	1.0	3
10	Acute Treatment for Migraine. JAMA - Journal of the American Medical Association, 2021, 325, 2346.	7.4	2
11	Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 155-166.	1.4	15
12	Lasmiditan for the acute treatment of migraine. Pain Management, 2021, 11, 437-449.	1.5	4
13	Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis. Journal of Clinical Pharmacology, 2021, 61, 1534-1544.	2.0	3
14	Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability. International Journal of Environmental Research and Public Health, 2021, 18, 246.	2.6	18
15	Une nouvelle g�n�ration de traitements sp�cifiques de la crise migraineuse : ditans et g�pants. Douleur Et Analgesie, 2020, 33, 153-156.	0.1	0
16	Lasmiditan for the Treatment of Migraines With or Without Aura in Adults. Psychopharmacology Bulletin, 2020, 50, 163-188.	0.0	0
17	Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors. Journal of Headache and Pain, 2022, 23, 26.	6.0	11
19	Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial. Expert Opinion on Drug Safety, 2022, 21, 1495-1503.	2.4	6

#	ARTICLE	IF	CITATIONS
20	Ditans: a new prospective for the therapy of migraine attack?. Neurological Sciences, 0, , .	1.9	1
21	Measuring, Analyzing, and Presenting Work Productivity Loss in Randomized Controlled Trials: A Scoping Review. Value in Health, 2022, , .	0.3	3
22	Efficacy of lasmiditan for the acute treatment of perimenstrual migraine. Cephalalgia, 2022, 42, 1467-1475.	3.9	5
23	Rimegepant, Ubrogapant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm. Clinical Journal of Pain, 2022, 38, 680-685.	1.9	5
24	Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial. Neurology and Therapy, 2022, 11, 1721-1734.	3.2	3
25	New Approaches to Shifting the Migraine Treatment Paradigm. Frontiers in Pain Research, 0, 3, .	2.0	11
27	UK medical cannabis registry: assessment of clinical outcomes in patients with headache disorders. Expert Review of Neurotherapeutics, 2023, 23, 85-96.	2.8	5
28	Long-term open-label and real-world studies of lasmiditan, ubrogapant, and rimegepant for the acute treatment of migraine attacks. Cephalalgia, 2023, 43, 033310242211370.	3.9	8
29	Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial. Cephalalgia, 2023, 43, 033310242311617.	3.9	2
30	Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy. Drug Design, Development and Therapy, 0, Volume 17, 1979-1993.	4.3	0
31	The 5-HT1F receptor as the target of ditans in migraine “ from bench to bedside. Nature Reviews Neurology, 0, , .	10.1	0
32	Major Targets involved in Clinical Management of Migraine. Current Neurovascular Research, 2023, 20, .	1.1	0
33	Dietary fatty acids improve perceived sleep quality, stress, and health in migraine: a secondary analysis of a randomized controlled trial. Frontiers in Pain Research, 0, 4, .	2.0	1
34	Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience. Frontiers in Neurology, 0, 14, .	2.4	0
35	5-HT1F agonists. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 43-50.	1.8	0